NCT01188733

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Octreotide is used to control variceal bleeding. However, octreotide has to be given through the vein and is effective for less than two hours. In this study the investigators determined whether a long-acting preparation of octreotide (Sandostatin LAR)given as an intra-muscular injection every month could decrease portal pressure, and thus be used to prevent variceal bleeding in patients with cirrhosis.

Conditions

• Cirrhosis
• Portal Hypertension
• Esophageal Varices

Interventions

Type	Name	Description
DRUG	Long acting octreotide 10mg	Comparison of different doses
DRUG	Long acting Octreotide 30mg	Comparison of drug doses
DRUG	Saline	Comparison of drug doses

Timeline

• Start date: 1998-06-01
• Primary completion: 2000-07-01
• Completion: 2000-12-01
• First posted: 2010-08-25
• Last updated: 2010-08-25